← Back to Newsroom

A pipeline update: three programs advance to next phase

Two complex-generic programs and one diagnostic assay reach the next stage of development.

Mynarix reported progress across its development portfolio, with three programs advancing to their next stage. The updates span an inhaled respiratory program, an anti-retroviral combination, and a new immunoassay.

Each program reflects the company’s focus on complex, difficult-to-replicate products where better engineering translates directly into better access and outcomes.

Further detail on program milestones will be shared as regulatory processes progress.